(Q45957649)

18 December 2017

review article

1 reference

title

Small cell lung cancer: current status of new chemotherapeutic agents. (English)

1 reference

18 December 2017

1 reference

Edelman MJ

1

1 reference

18 December 2017

Gandara DR

series ordinal

2

1 reference

18 December 2017

publication date

1 April 1998

1 reference

18 December 2017

Critical Reviews in Oncology Hematology

published in

1 reference

18 December 2017

volume

27

1 reference

18 December 2017

issue

3

1 reference

18 December 2017

page(s)

211-220

1 reference

18 December 2017

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

1 reference

7 January 2021

Alkylating agents in bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Chemotherapy in Small Cell Lung Cancer: The Current State of the Art.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Small-Cell Carcinoma of Lung: Reinduction Therapy After Late Relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study. Groupe d'Oncologie de Langue Française

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Taxanes: a new class of antitumor agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Paclitaxel: what schedule? What dose?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Gemcitabine: current status of phase I and II trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Oral etoposide and palliative treatment for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Taxol sensitizes human ovarian cancer cells to radiation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900002-X

7 January 2021

10.1016/S1040-8428(98)00002-X

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017